{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T20:21:07Z","timestamp":1784233267461,"version":"3.55.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T00:00:00Z","timestamp":1643846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T00:00:00Z","timestamp":1643846400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100008089","name":"Fondazione Internazionale Menarini","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008089","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Health Econ"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Early discharge (ED) from hospital and outpatient parenteral antibiotic therapy (OPAT) are effective approaches for the management of a range of infections, including acute bacterial skin and skin structure infections (ABSSSI). Strategies that facilitate ED, thereby reducing complications such as healthcare-acquired infection whilst enhancing patient quality of life, are being increasingly adopted in line with good antimicrobial stewardship practice. This study presents a cost-minimisation analysis for the use of oritavancin at ED versus relevant comparators from a National Health Service (NHS) and personal and social services United Kingdom perspective.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A cost-minimisation model considering adult patients with ABSSSI with suspected or confirmed methicillin-resistant <jats:italic>Staphylococcus aureus<\/jats:italic> (MRSA) infection, was developed based on publicly available NHS costs, practice guidelines for ABSSSI and clinical expert\u2019s opinion. Cost of treatment and treatment days were compared for oritavancin at ED to dalbavancin, teicoplanin, daptomycin and linezolid.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Following the empiric use of either flucloxacillin or vancomycin in the inpatient setting, oritavancin was compared to OPAT with dalbavancin, teicoplanin and daptomycin, and oral linezolid from day 4 of treatment. Oritavancin at ED reduced treatment duration by 0.8\u00a0days and led to cost savings of \u00a3281 in comparison to dalbavancin. In comparison to teicoplanin, daptomycin and linezolid, oritavancin reduced treatment duration by 5 days, with marginally higher costs (\u00a3446, \u00a3137, and \u00a31,434, respectively).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Oritavancin, used to support ED, is associated with lower costs compared with dalbavancin and reduced treatment duration relative to all comparators. Its use would support an ED approach in MRSA ABSSSI management.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10198-022-01432-2","type":"journal-article","created":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T06:03:47Z","timestamp":1643868227000},"page":"1371-1381","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Cost-minimisation analysis of oritavancin for the treatment of acute bacterial skin and skin structure infections from a United Kingdom perspective"],"prefix":"10.1007","volume":"23","author":[{"given":"Daniela","family":"Zinzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioanna","family":"Vlachaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edel","family":"Falla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1159-5241","authenticated-orcid":false,"given":"Theo","family":"Mantopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilip","family":"Nathwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,3]]},"reference":[{"issue":"2","key":"1432_CR1","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1097\/QCO.0000000000000239","volume":"29","author":"S Esposito","year":"2016","unstructured":"Esposito, S., Noviello, S., Leone, S.: Epidemiology and microbiology of skin and soft tissue infections. Curr. Opin. Infect. Dis. 29(2), 109\u2013115 (2016)","journal-title":"Curr. Opin. Infect. Dis."},{"issue":"4","key":"1432_CR2","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.jemermed.2014.12.001","volume":"48","author":"CV Pollack Jr","year":"2015","unstructured":"Pollack, C.V., Jr., Amin, A., Ford, W.T., Jr., Finley, R., Kaye, K.S., Nguyen, H.H., et al.: Acute bacterial skin and skin structure infections (ABSSSI): practice guidelines for management and care transitions in the emergency department and hospital. J. Emerg. Med. 48(4), 508\u2013519 (2015)","journal-title":"J. Emerg. Med."},{"key":"1432_CR3","unstructured":"USFDA. Guidance for industry acute bacterial skin and skin structure infections: developing drugs for treatment. Center for Drug Evaluation and Research (CDER), Food and Drug Administration https:\/\/www.fda.gov\/media\/71052\/download (2013, accessed Jul 01, 2020)"},{"issue":"3","key":"1432_CR4","first-page":"603","volume":"28","author":"SYC Tong","year":"2015","unstructured":"Tong, S.Y.C., Davis, J.S., Eichenberger, E., Holland, T.L., Fowler, V.G.: Staphylococcus aureus infections: epidemiology pathophysiology. Clin. Manif. Manag. 28(3), 603\u2013661 (2015)","journal-title":"Clin. Manif. Manag."},{"key":"1432_CR5","unstructured":"NHS. Skin and Soft Tissue Infections (SSTI) Antibiotic Guidelines (Adult), https:\/\/www.srft.nhs.uk\/EasysiteWeb\/getresource.axd?AssetID=8102&type=full&servicetype=Inline (2019, accessed Jul 24, 2020)"},{"issue":"10","key":"1432_CR6","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1093\/jac\/dkv179","volume":"70","author":"DM Livermore","year":"2015","unstructured":"Livermore, D.M., Mushtaq, S., Warner, M., James, D., Kearns, A., Woodford, N.: Pathogens of skin and skin-structure infections in the UK and their susceptibility to antibiotics, including ceftaroline. J. Antimicrob. Chemother. 70(10), 2844\u20132853 (2015)","journal-title":"J. Antimicrob. Chemother."},{"key":"1432_CR7","unstructured":"ECDC. European Centre for Disease Prevention and Control; Surveillance of antimicrobial resistance in Europe 2018; Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net), https:\/\/www.ecdc.europa.eu\/sites\/default\/files\/documents\/surveillance-antimicrobial-resistance-Europe-2018.pdf (2018, accessed Aug 08, 2020)"},{"issue":"5","key":"1432_CR8","doi-asserted-by":"publisher","first-page":"720","DOI":"10.3201\/eid1405.070153","volume":"14","author":"A Hayward","year":"2008","unstructured":"Hayward, A., Knott, F., Petersen, I., Livermore, D.M., Duckworth, G., Islam, A., et al.: Increasing hospitalizations and general practice prescriptions for community-onset staphylococcal disease England. Emerg. Infect. Dis. 14(5), 720\u2013726 (2008)","journal-title":"Emerg. Infect. Dis."},{"key":"1432_CR9","unstructured":"Health Protection Agency. (2012) English National Point Prevalence Survey on Healthcare Associated Infections and Antimicrobial Use, https:\/\/webarchive.nationalarchives.gov.uk\/20140714095446\/http:\/\/www.hpa.org.uk\/webc\/HPAwebFile\/HPAweb_C\/1317134304594 (2011, accessed 24 Jul 2020)"},{"key":"1432_CR10","unstructured":"Department of Health; Technical Guidance for the 2012\/13 Operating Framework, https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/216413\/dh_132045.pdf (2011, accessed 08 Aug 2020)"},{"issue":"9","key":"1432_CR11","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1093\/jac\/dks193","volume":"67","author":"M Dryden","year":"2012","unstructured":"Dryden, M., Saeed, K., Townsend, R., Winnard, C., Bourne, S., Parker, N., et al.: Antibiotic stewardship and early discharge from hospital: impact of a structured approach to antimicrobial management. J. Antimicrob. Chemother. 67(9), 2289\u20132296 (2012)","journal-title":"J. Antimicrob. Chemother."},{"issue":"2","key":"1432_CR12","doi-asserted-by":"publisher","first-page":"e10","DOI":"10.1093\/cid\/ciu296","volume":"59","author":"DL Stevens","year":"2014","unstructured":"Stevens, D.L., Bisno, A.L., Chambers, H.F., Dellinger, E.P., Goldstein, E.J., Gorbach, S.L., et al.: Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 59(2), e10-52 (2014)","journal-title":"Clin. Infect. Dis."},{"issue":"1","key":"1432_CR13","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13017-018-0219-9","volume":"13","author":"M Sartelli","year":"2018","unstructured":"Sartelli, M., Guirao, X., Hardcastle, T.C., Kluger, Y., Boermeester, M.A., Ra\u015fa, K., et al.: 2018 WSES\/SIS-E consensus conference: recommendations for the management of skin and soft-tissue infections. World J. Emerg. Surg. 13(1), 58 (2018)","journal-title":"World J. Emerg. Surg."},{"key":"1432_CR14","unstructured":"Fulton, R., Doherty, L., Gill, D.H.A., Harper, C., Jenkinson, H., Loughrey, A., Martin, E., Mullan, J., Mullan, C., Scott, M., Witherow, A.: Guidelines on the management of cellulitis in adults (CREST), https:\/\/www.rcem.ac.uk\/docs\/External%20Guidance\/10n.%20Guidelines%20on%20the%20management%20of%20cellulitis%20in%20adults%20(CREST,%202005.pdf (2005, accessed 08 Jul 2020)"},{"issue":"1","key":"1432_CR15","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.ijantimicag.2014.04.007","volume":"44","author":"C Eckmann","year":"2014","unstructured":"Eckmann, C., Lawson, W., Nathwani, D., Solem, C.T., Stephens, J.M., Macahilig, C., et al.: Antibiotic treatment patterns across Europe in patients with complicated skin and soft-tissue infections due to meticillin-resistant Staphylococcus aureus: a plea for implementation of early switch and early discharge criteria. Int. J. Antimicrob. Agents. 44(1), 56\u201364 (2014)","journal-title":"Int. J. Antimicrob. Agents."},{"issue":"Suppl 3","key":"1432_CR16","doi-asserted-by":"publisher","first-page":"S193","DOI":"10.1093\/cid\/ciz002","volume":"68","author":"KS Kaye","year":"2019","unstructured":"Kaye, K.S., Petty, L.A., Shorr, A.F., Zilberberg, M.D.: Current epidemiology, etiology, and burden of acute skin infections in the United States. Clin. Infect. Dis. 68(Suppl 3), S193\u2013S199 (2019)","journal-title":"Clin. Infect. Dis."},{"issue":"3","key":"1432_CR17","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.diagmicrobio.2009.02.005","volume":"64","author":"HT Hatoum","year":"2009","unstructured":"Hatoum, H.T., Akhras, K.S., Lin, S.J.: The attributable clinical and economic burden of skin and skin structure infections in hospitalized patients: a matched cohort study. Diagn. Microbiol. Infect. Dis. 64(3), 305\u2013310 (2009)","journal-title":"Diagn. Microbiol. Infect. Dis."},{"issue":"9","key":"1432_CR18","doi-asserted-by":"publisher","first-page":"E377","DOI":"10.1111\/1469-0691.12235","volume":"19","author":"J Garau","year":"2013","unstructured":"Garau, J., Ostermann, H., Medina, J., Avila, M., McBride, K., Blasi, F.: Current management of patients hospitalized with complicated skin and soft tissue infections across Europe (2010\u20132011): assessment of clinical practice patterns and real-life effectiveness of antibiotics from the REACH study. Clin. Microbiol. Infect. 19(9), E377\u2013E385 (2013)","journal-title":"Clin. Microbiol. Infect."},{"issue":"10","key":"1432_CR19","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1111\/1469-0691.12632","volume":"20","author":"D Nathwani","year":"2014","unstructured":"Nathwani, D., Eckmann, C., Lawson, W., Stephens, J.M., Macahilig, C., Solem, C.T., et al.: Pan-European early switch\/early discharge opportunities exist for hospitalized patients with methicillin-resistant Staphylococcus aureus complicated skin and soft tissue infections. Clin. Microbiol. Infect. 20(10), 993\u20131000 (2014)","journal-title":"Clin. Microbiol. Infect."},{"issue":"3","key":"1432_CR20","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s10096-013-1956-z","volume":"33","author":"RA Seaton","year":"2014","unstructured":"Seaton, R.A., Johal, S., Coia, J.E., Reid, N., Cooper, S., Jones, B.L.: Economic evaluation of treatment for MRSA complicated skin and soft tissue infections in Glasgow hospitals. Eur. J. Clin. Microbiol. Infect. Dis. 33(3), 305\u2013311 (2014)","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"issue":"2","key":"1432_CR21","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1093\/jac\/dkm210","volume":"60","author":"PC Matthews","year":"2007","unstructured":"Matthews, P.C., Conlon, C.P., Berendt, A.R., Kayley, J., Jefferies, L., Atkins, B.L., et al.: Outpatient parenteral antimicrobial therapy (OPAT): is it safe for selected patients to self-administer at home? A retrospective analysis of a large cohort over 13 years. J. Antimicrob. Chemother. 60(2), 356\u2013362 (2007)","journal-title":"J. Antimicrob. Chemother."},{"issue":"12","key":"1432_CR22","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1086\/420939","volume":"38","author":"AD Tice","year":"2004","unstructured":"Tice, A.D., Rehm, S.J., Dalovisio, J.R., Bradley, J.S., Martinelli, L.P., Graham, D.R., et al.: Practice guidelines for outpatient parenteral antimicrobial therapy. IDSA guidelines. Clin. Infect. Dis. 38(12), 1651\u20131672 (2004)","journal-title":"Clin. Infect. Dis."},{"issue":"1","key":"1432_CR23","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s40121-016-0145-7","volume":"6","author":"PJ Anastasio","year":"2017","unstructured":"Anastasio, P.J., Wolthoff, P., Galli, A., Fan, W.: Single-dose oritavancin compared to standard of care IV antibiotics for acute bacterial skin and skin structure infection in the outpatient setting: a retrospective real-world study. Infect. Dis. Ther. 6(1), 115\u2013128 (2017)","journal-title":"Infect. Dis. Ther."},{"key":"1432_CR24","unstructured":"Menarini.: Orbactiv, INN-oritavancin, Summary of Product Characterstics (SmPC), https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/orbactiv-epar-product-information_en.pdf (accessed 24 Jul 2020)"},{"issue":"2","key":"1432_CR25","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.ijantimicag.2016.04.023","volume":"48","author":"D Nathwani","year":"2016","unstructured":"Nathwani, D., Dryden, M., Garau, J.: Early clinical assessment of response to treatment of skin and soft-tissue infections: how can it help clinicians? Perspectives from Europe. Int. J. Antimicrob. Agents. 48(2), 127\u2013136 (2016)","journal-title":"Int. J. Antimicrob. Agents."},{"key":"1432_CR26","unstructured":"EMA.: European Medicines Agency; Orbactiv, https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/orbactiv (2015, accessed 15 Jul 2020)"},{"issue":"23","key":"1432_CR27","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1056\/NEJMoa1310422","volume":"370","author":"GR Corey","year":"2014","unstructured":"Corey, G.R., Kabler, H., Mehra, P., Gupta, S., Overcash, J.S., Porwal, A., et al.: Single-dose oritavancin in the treatment of acute bacterial skin infections. N. Engl. J. Med. 370(23), 2180\u20132190 (2014)","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"1432_CR28","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1093\/cid\/ciu778","volume":"60","author":"GR Corey","year":"2015","unstructured":"Corey, G.R., Good, S., Jiang, H., Moeck, G., Wikler, M., Green, S., et al.: Single-dose oritavancin versus 7\u201310 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study. Clin. Infect. Dis. 60(2), 254\u2013262 (2015)","journal-title":"Clin. Infect. Dis."},{"issue":"8","key":"1432_CR29","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1185\/03007995.2015.1058248","volume":"31","author":"H Thom","year":"2015","unstructured":"Thom, H., Thompson, J.C., Scott, D.A., Halfpenny, N., Sulham, K., Corey, G.R.: Comparative efficacy of antibiotics for the treatment of acute bacterial skin and skin structure infections (ABSSSI): a systematic review and network meta-analysis. Curr. Med. Res. Opin. 31(8), 1539\u20131551 (2015)","journal-title":"Curr. Med. Res. Opin."},{"issue":"4","key":"1432_CR30","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1093\/jac\/dkr554","volume":"67","author":"C Marwick","year":"2012","unstructured":"Marwick, C., Rae, N., Irvine, N., Davey, P.: Prospective study of severity assessment and management of acute medical admissions with skin and soft tissue infection. J. Antimicrob. Chemother. 67(4), 1016\u20131019 (2012)","journal-title":"J. Antimicrob. Chemother."},{"key":"1432_CR31","unstructured":"BNF.: Joint Formulary Committee. British National Formulary. Medicines Complete, https:\/\/www.medicinescomplete.com\/#\/content\/bnf\/ (2020, accessed 26 Apr 2019)"},{"key":"1432_CR32","unstructured":"PSSRU.: Unit costs of health and social care (PSSRU) https:\/\/www.pssru.ac.uk\/pub\/uc\/uc2019\/services.pdf (2019, accessed 22 Jun 2020)"},{"key":"1432_CR33","first-page":"2018","volume-title":"A unit costs of health and social care. Personal social services research unit","author":"LBA Curtis","year":"2019","unstructured":"Curtis, L.B.A.: A unit costs of health and social care. Personal social services research unit, p. 2018. University of Kent, Canterbury (2019)"},{"key":"1432_CR34","unstructured":"PSSRU.: NHS cost inflation index, Unit Costs of Health and Social Care (PSSRU) 2019, https:\/\/www.pssru.ac.uk\/pub\/uc\/uc2019\/sources-of-information.pdf (2019, accessed 22 Jun 2020)"},{"key":"1432_CR35","unstructured":"NHS.: National Cost Collection: National Schedule of NHS costs\u2014year 2018\u20132019\u2014NHS trust and NHS foundation trusts, https:\/\/improvement.nhs.uk\/resources\/national-cost-collection\/#ncc1819 (2018, accessed 22 Jun 2020)"},{"key":"1432_CR36","unstructured":"BNF.: Joint Formulary Committee.\u00a0Dalbavancin (IV) Correvio UK Ltd. British National Formulary\u00a0(online) London: BMJ Group and Pharmaceutical Press, https:\/\/www.medicinescomplete.com\/#\/content\/bnf\/_776052829?hspl=Dalbavancin (2020, accessed 22 Jun 2020)"},{"issue":"12","key":"1432_CR37","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.3111\/13696998.2015.1078339","volume":"18","author":"V Ektare","year":"2015","unstructured":"Ektare, V., Khachatryan, A., Xue, M., Dunne, M., Johnson, K., Stephens, J.: Assessing the economic value of avoiding hospital admissions by shifting the management of gram+ acute bacterial skin and skin-structure infections to an outpatient care setting. J. Med. Econ. 18(12), 1092\u20131101 (2015)","journal-title":"J. Med. Econ."},{"issue":"1","key":"1432_CR38","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1186\/s12913-018-3751-0","volume":"18","author":"SS AlmarzokyAbuhussain","year":"2018","unstructured":"AlmarzokyAbuhussain, S.S., Burak, M.A., Kohman, K.N., Jacknin, G., Tart, S.B., Hobbs, A.L.V., et al.: Patient preferences for treatment of acute bacterial skin and skin structure infections in the emergency department. BMC Health Serv. Res. 18(1), 932 (2018)","journal-title":"BMC Health Serv. Res."},{"key":"1432_CR39","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.jgar.2020.02.002","volume":"22","author":"A Soriano","year":"2020","unstructured":"Soriano, A., Stefani, S., Pletz, M.W., Menichetti, F.: Antimicrobial stewardship in patients with acute bacterial skin and skin-structure infections: an international Delphi consensus. J. Glob. Antimicrob. Resist. 22, 296\u2013301 (2020)","journal-title":"J. Glob. Antimicrob. Resist."},{"issue":"1","key":"1432_CR40","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s40801-020-00192-w","volume":"7","author":"LE Brownell","year":"2020","unstructured":"Brownell, L.E., Adamsick, M.L., McCreary, E.K., Vanderloo, J.P., Ernst, E.J., Jackson, E.R., et al.: Clinical outcomes and economic impact of oritavancin for gram-positive infections: a single Academic Medical Center Health System Experience. Drugs Real World Outcomes. 7(1), 13\u201319 (2020)","journal-title":"Drugs Real World Outcomes."},{"issue":"Suppl 2","key":"1432_CR41","first-page":"ii37","volume":"51","author":"D Nathwani","year":"2003","unstructured":"Nathwani, D.: Impact of methicillin-resistant Staphylococcus aureus infections on key health economic outcomes: does reducing the length of hospital stay matter? J. Antimicrob. Chemother. 51(Suppl 2), ii37-44 (2003)","journal-title":"J. Antimicrob. Chemother."},{"issue":"suppl 3","key":"1432_CR42","doi-asserted-by":"publisher","first-page":"S239","DOI":"10.1093\/cid\/cir1047","volume":"54","author":"A Tice","year":"2012","unstructured":"Tice, A.: Oritavancin: a new opportunity for outpatient therapy of serious infections. Clin. Infect. Dis. 54(suppl 3), S239\u2013S243 (2012)","journal-title":"Clin. Infect. Dis."},{"issue":"12","key":"1432_CR43","doi-asserted-by":"publisher","first-page":"ofz475","DOI":"10.1093\/ofid\/ofz475","volume":"6","author":"TP Lodise","year":"2019","unstructured":"Lodise, T.P., Palazzolo, C., Reksc, K., Packnett, E., Redell, M.: Comparisons of 30-day admission and 30-day total healthcare costs between patients who were treated with oritavancin or vancomycin for a skin infection in the outpatient setting. Open Forum Infect. Dis. 6(12), ofz475 (2019)","journal-title":"Open Forum Infect. Dis."},{"issue":"6","key":"1432_CR44","first-page":"752","volume":"22","author":"IS Jensen","year":"2016","unstructured":"Jensen, I.S., Wu, E., Fan, W., Lodise, T.P., Nicolau, D.P., Dufour, S., et al.: Use of oritavancin in moderate-to-severe ABSSSI patients requiring IV antibiotics: a US Payer Budget Impact Analysis. J. Manag. Care Spec. Pharm. 22(6), 752\u2013764 (2016)","journal-title":"J. Manag. Care Spec. Pharm."},{"issue":"9","key":"1432_CR45","doi-asserted-by":"publisher","first-page":"e031356","DOI":"10.1136\/bmjopen-2019-031356","volume":"9","author":"U Restelli","year":"2019","unstructured":"Restelli, U., Bonfanti, M., Croce, D., Grau, S., Metallidis, S., Moreno Guill\u00e9n, S., et al.: Organisational and financial consequences of the early discharge of patients treated for acute bacterial skin and skin structure infection and osteomyelitis in infectious disease departments in Greece, Italy and Spain: a scenario analysis. BMJ Open 9(9), e031356 (2019)","journal-title":"BMJ Open"},{"issue":"Suppl 4","key":"1432_CR46","first-page":"iv41","volume":"65","author":"GR Corey","year":"2010","unstructured":"Corey, G.R., Wilcox, M.H., Talbot, G.H., Thye, D., Friedland, D., Baculik, T.: CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J. Antimicrob. Chemother. 65(Suppl 4), iv41-51 (2010)","journal-title":"J. Antimicrob. Chemother."},{"issue":"3","key":"1432_CR47","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s10156-012-0501-9","volume":"19","author":"N Aikawa","year":"2013","unstructured":"Aikawa, N., Kusachi, S., Mikamo, H., Takesue, Y., Watanabe, S., Tanaka, Y., et al.: Efficacy and safety of intravenous daptomycin in Japanese patients with skin and soft tissue infections. J. Infect. Chemother. 19(3), 447\u2013455 (2013)","journal-title":"J. Infect. Chemother."},{"issue":"6","key":"1432_CR48","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/j.amjsurg.2009.08.045","volume":"199","author":"KM Itani","year":"2010","unstructured":"Itani, K.M., Dryden, M.S., Bhattacharyya, H., Kunkel, M.J., Baruch, A.M., Weigelt, J.A.: Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft-tissue infections proven to be caused by methicillin-resistant Staphylococcus aureus. Am. J. Surg. 199(6), 804\u2013816 (2010)","journal-title":"Am. J. Surg."},{"issue":"Suppl 4","key":"1432_CR49","first-page":"iv3","volume":"65","author":"MH Wilcox","year":"2010","unstructured":"Wilcox, M.H., Corey, G.R., Talbot, G.H., Thye, D., Friedland, D., Baculik, T.: CANVAS 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J. Antimicrob. Chemother. 65(Suppl 4), iv3\u2013iv5 (2010)","journal-title":"J. Antimicrob. Chemother."},{"key":"1432_CR50","unstructured":"Menarini: Menarini data on file: Cost price Oritavancin (2020)"},{"key":"1432_CR51","unstructured":"NHS: NHS 2019\/20 National Tariff Payment System: proposed national prices and prices for emergency care services. https:\/\/www.england.nhs.uk\/pay-syst\/national-tariff\/2019-20-payment-reform-proposals\/. Accessed 22 June 2020"},{"key":"1432_CR52","unstructured":"Antibiotic Steering Committee, Antibiotic Guidelines (Adult): Skin and Soft Tissue Infections (SSTI). Salford Royal NHS Foundation Trust (2014)"}],"container-title":["The European Journal of Health Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-022-01432-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10198-022-01432-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-022-01432-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T17:08:30Z","timestamp":1665421710000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10198-022-01432-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,3]]},"references-count":52,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["1432"],"URL":"https:\/\/doi.org\/10.1007\/s10198-022-01432-2","relation":{},"ISSN":["1618-7598","1618-7601"],"issn-type":[{"value":"1618-7598","type":"print"},{"value":"1618-7601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,3]]},"assertion":[{"value":"5 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Daniela Zinzi and Ioanna Vlachaki are employees of Menarini group. Edel Falla and Theo Mantopoulos received consulting fees from Menarini. Dilip Nathwani supported the study as the clinical expert and received personal fees from Menarini for his support in the present study. Dilip Nathwani has also received honoraria from Menarini outside the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}